Navigation Links
A Wristwatch For Detecting Malaria

A new wristwatch has been invented in South Africa which is capable of detecting the malaria parasites in the body of the wearer. This is done by automatically collecting the blood samples //of the person who is wearing the watch, and if the malaria parasite is found, it warns the person. Gervan Lubbe has developed the watch which obtains blood samples with a microscopic needle that automatically penetrates the skin twice during the day and twice at night.

An alarm sounds if the parasite count is above 50, before the first symptoms appear.

According to Lubbe, at that point an antidote in the form of tablets should be consumed and, within 48 hours, all traces of malaria are eliminated from the body. Malaria is the single biggest killer on the African continent, claiming close to three million lives a year.

Traditionally when signs of malaria become apparent, the parasite count is at approximately 3,000, at which stage quinine (the malaria drug) needs to be administered which is reported to be more dangerous than the parasite itself. Lubbe's company Gervans Trading is now developing the device for millions of employees of a major mining group.

With the wristwatch, each miner will walk through a scanner, similar to a metal detector, and the watch's radio frequency will transmit the wearer's information to a central computer.

‘My biggest concern is whether we'll be able to supply the world market,’ said Lubbe.

Battery operated and water resistant, with durable rubber to withstand high-frequency vibrations, the watch's alarm rings every 35 days to remove the small metal sieve and wash the old blood away. The watch will be available soon from travel agents and outdoor stores.

Edited IANS
'"/>




Page: 1

Related medicine news :

1. Detecting anomalies in heart rythm
2. Detecting brain aneurysms
3. Detecting Colorectal Cancer
4. Photographs An Effective Tool In Detecting Skin Cancer
5. Mammograms The Best In Detecting Breast Cancer
6. Detecting Lung Cancer Early
7. Detecting Lung Cancer In Its Initial Stages
8. A New Way Of Detecting Osteoporosis
9. Detecting DNA Damage With In-Vivo Alkaline Comet Assay
10. CT Pulmonary Angiography Scan More Effective In Detecting Dangerous Blood Clots In The Legs
11. Researchers Develop Device For Detecting Atherosclerotic Plaques
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Wristwatch For Detecting Malaria

(Date:12/1/2008)... EXTON, Pa., Dec. 1 Vir...unced that the company submitted a supplemental,B...od and Drug Administration,(FDA) for Cinryze(TM) ...cks of,hereditary angioedema (HAE). , The ... data from a pivotal,Phase 3 acute treatment stud...
(Date:12/1/2008)... Alcohol, nicotine use, personality illnesses com...althDay News) -- Psychiatric disorders are common ...eek treatment, a new report shows. , To reach t...ore than 5,000 respondents, aged 19 to 25, who too...ohol and Related Conditions. , The study found ...
(Date:12/1/2008)... , A new analysis of the National Cancer Institut...in five older women experience delayed or incomple... surgery, and that this suboptimal care can lead t...eill Cornell Medical College and colleagues found ...early 8,000 breast cancer registry patients aged 6...
(Date:12/1/2008)... WASHINGTON, Dec. 1 /PRNewswire-USNewswire/ -- ...e release of a model state legislative resolution ...). AUL urges state legislatures to adopt the reso...ssions. , , Dr. Charmaine Yoest, AUL Presid...ice Act, endangers women,s health. It protects an...
Breaking Medicine News(10 mins):Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 2Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 3Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 4Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 5Health News:Few Young Adults Seek Treatment for Psych Disorders 2Health News:Delays in radiation therapy lead to increased breast cancer recurrence 2Health News:Americans United for Life Urges State Legislatures to Oppose Federal Power Grab: Provides Model Resolution Denouncing Freedom of Choice Act (FOCA) 2
...k we had carried a story about Wal-mart’s foray in... a pilot project which involved the lease of medic... 76 clinics actively functioning at the Wal mart s...uring the meeting of the 4th Annual World Health C...
...nd busier an NHS hospital is, the higher the MRSA ...versity Business School has revealed. The impact...MRSA infections in NHS hospitals study looked at h... imposed by hospital insurers — and the premium di...
...st vaccination of sixth-grader girls to prevent ce...-Texas Governor Rick Perry. //The move sees that T...ixth-grade girls to be vaccinated against a sexual...al cancer. Yesterday, the Texas House gave the go...
...bility and resources for public health and tacklin...cils rather than with the NHS, argues an expert in...m University says that partnerships between local ...d then become a true meeting of the two sides of h...
Other Medicine News:Health News:Better Risk Management Could Cut MRSA Infection Rates 2Health News:Local Councils Should Be Responsible for Tackling Health Inequalities 2
(Date:12/1/2008)...uled for Tuesday, December 9 at 11:00 am ET to Dis...OUTH SAN FRANCISCO, Calif., Dec. 1 /PRNewswire-F...: SNSS ), a biopharmaceutical company focused on...logy therapeutics, today announced new data from i...(AML) will be presented during the 50th American S...
(Date:11/28/2008)...ovember 28 German biotech company,...ialized HIV monitoring and,AIDS patient follow-up.... In,the year 2008, 2.5 million patient tests hav...ghly affordable "CyFlow" system, supporting alread.... Due to introduction of the,Partec innovation, t...
(Date:11/26/2008)...bjects , , FRANKLIN, Mass., Nov. 26 /PRNews...Board: PLCSF) announced today that it has received...tration (FDA) for its U.S. pivotal trial to study ...em(TM) and associated therapy in the prevention o...he FDA also approved PLC,s request to expand their...
(Date:11/25/2008)...if., Nov. 25 Poniard,Ph...ceutical company focused on,innovative oncology t...g,strategic alternatives for its preclinical rese...cus its resources on the clinical development of p...port the initial commercialization of,picoplatin ...
Breaking Medicine Technology:Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3Liver Transplant Patients at Higher Cancer Risk 27261 1Liver Transplant Patients at Higher Cancer Risk 27261 2PURE Bioscience to Announce Fourth Quarter and Fiscal 2008 Results 8212 1PURE Bioscience to Announce Fourth Quarter and Fiscal 2008 Results 8212 2Hologic Inc To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday November 11 2008 27255 1Hologic Inc To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday November 11 2008 27255 2Children 26apos 3Bs National Experts Presenting at American Academy of Pediatrics Conference 27252 1Children 26apos 3Bs National Experts Presenting at American Academy of Pediatrics Conference 27252 2
...ournal of Clinical Oncology -, NEW YORK, July 06, ...e II study - which will be published in the August...y (JCO) and are now,available as an Early Release ...o.org/">www.jco.org - demonstrate that,ixabepilon...compound, has activity in patients with metastatic...
...5, an Investigational NNRTI,from Tibotec, YARDLEY,...ongoing Phase 3 studies (DUET-1 and DUET-2) showed...mented non-nucleoside reverse,transcriptase inhibi... reached an undetectable viral load (defined as ac...A copies/mL) with,TMC125 (etravirine), Tibotec,s i...
Other Medicine Technology:Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 2Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 3Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 4TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 2TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 3TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 4
11.5 mm curved hook. Flat serrated handle with polished finish. Overall length: 5.9 inches.
Designed for manipulating one piece lenses. The "Y: hook is excellent for capturing haptics and centering the lens. Straight shaft with "Y" shaped tip. Round knurled handle with dull finish. Overall
0.2 mm Sinskey hook with shaft angled 45 degrees, 10 mm from tip to bend. Flat smooth handle with polished finish. Overall length: 4.6 inches.
0.3 mm hook angled 45 degrees, 9 mm from tip to bend. Flat smooth handle with polished finish. Overall length: 4.6 inches.
Medicine Products: